The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia : An in vitro study
(2019) In Phytotherapy Research 33(9). p.2457-2464- Abstract
The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the... (More)
The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the upregulation of tumour necrosis factor-related apoptosis-inducing ligand in hPBMC. Interestingly, the levels of proinflammatory cytokines IL-6 and IL-8 were also increased. Furthermore, Cernitin® had significantly increased the level of IL-10 in BPH-1 and WPMY-1 cells. The level of IL-6 was also significantly increased in these cells although both T60 and GBX inhibited STAT-3 phosphorylation. Moreover, Cernitin® formulas had significantly reduced androgen receptor and prostate-specific antigen protein expression in stromal cells (p <.05). Treatment with GBX and T60 had significantly inhibited proliferation of BPH (p <.001) and stromal cells (p <.05), in a dose-dependent manner. Taken together, treatment with Cernitin® showed to regulate cytokines level in both prostatic cell lines and hPBMCs and it was associated with decreased androgen receptor and prostate-specific antigen levels WPMY-1 cells.
(Less)
- author
- Dizeyi, Nishtman LU ; Mattisson, Ingrid Yao LU ; Ramnemark, Lena ; Grabe, Magnus LU and Abrahamsson, Per Anders LU
- organization
-
- Molecular genetic reproductive medicine, Malmö (research group)
- Urological research, Malmö (research group)
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- Cardiovascular Research - Immunity and Atherosclerosis (research group)
- Urological cancer, Malmö (research group)
- publishing date
- 2019-07-25
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- benign prostatic hyperplasia, Cernitin®, cytokines, prostatitis
- in
- Phytotherapy Research
- volume
- 33
- issue
- 9
- pages
- 2457 - 2464
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85069887947
- pmid:31342610
- ISSN
- 0951-418X
- DOI
- 10.1002/ptr.6438
- language
- English
- LU publication?
- yes
- id
- 3da7974e-bd25-4af8-9003-7460845d9b40
- date added to LUP
- 2019-08-28 16:13:39
- date last changed
- 2024-08-21 05:43:35
@article{3da7974e-bd25-4af8-9003-7460845d9b40, abstract = {{<p>The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the upregulation of tumour necrosis factor-related apoptosis-inducing ligand in hPBMC. Interestingly, the levels of proinflammatory cytokines IL-6 and IL-8 were also increased. Furthermore, Cernitin® had significantly increased the level of IL-10 in BPH-1 and WPMY-1 cells. The level of IL-6 was also significantly increased in these cells although both T60 and GBX inhibited STAT-3 phosphorylation. Moreover, Cernitin® formulas had significantly reduced androgen receptor and prostate-specific antigen protein expression in stromal cells (p <.05). Treatment with GBX and T60 had significantly inhibited proliferation of BPH (p <.001) and stromal cells (p <.05), in a dose-dependent manner. Taken together, treatment with Cernitin® showed to regulate cytokines level in both prostatic cell lines and hPBMCs and it was associated with decreased androgen receptor and prostate-specific antigen levels WPMY-1 cells.</p>}}, author = {{Dizeyi, Nishtman and Mattisson, Ingrid Yao and Ramnemark, Lena and Grabe, Magnus and Abrahamsson, Per Anders}}, issn = {{0951-418X}}, keywords = {{benign prostatic hyperplasia; Cernitin®; cytokines; prostatitis}}, language = {{eng}}, month = {{07}}, number = {{9}}, pages = {{2457--2464}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Phytotherapy Research}}, title = {{The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia : An in vitro study}}, url = {{http://dx.doi.org/10.1002/ptr.6438}}, doi = {{10.1002/ptr.6438}}, volume = {{33}}, year = {{2019}}, }